Key Players
Competitive Landscape
Hepatic sarcopenia nutrition market includes liver-specific amino-acid suppliers, broad medical nutrition companies and compact-protein specialists. Otsuka Pharmaceutical and Ajinomoto are focusing on liver or amino-acid nutrition, while Abbott, Nestle Health Science and Danone Nutricia offer wider oral nutrition portfolios. Fresenius Kabi, Meiji Holdings and Medtrition provide concentrated liquids and modular protein formats. Companies are focusing on protein quantity, smaller serving volume, flavour choice and availability after hospital discharge. Expansion of suitable product ranges is expected to support the customer base across hospital and homecare channels.
During 2025 and 2026, notable companies increased focus on lower-volume formats, flavour choice and continued product access. In October 2025, Danone Nutricia launched savory Fortimel PlantBased Protein options for disease-related malnutrition [17]. In March 2025, Medtrition launched ProSource Cup with 20 g protein in a low-volume cup [9], while Abbott continued institutional ordering for Ensure Plus High Protein during 2026 [15]. These developments are expected to support repeated product intake across different hospital and home-use schedules.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In October 2025, Danone Nutricia launched savory Fortimel PlantBased Protein [17]. | Repeat users need more flavor options. | Medical nutrition portfolios are widening beyond sweet drinks. | Savory formats can reduce flavor fatigue. |
| In March 2025, Medtrition launched ProSource Cup with 20 g protein [9]. | Patients need high protein in smaller volumes. | Modular nutrition is moving into compact cups. | Low-volume dosing can support transition care. |
| In 2026, Abbott documented institutional ordering for Ensure Plus High Protein [15]. | Patients require supervised access to therapeutic nutrition. | Hospital initiation remains linked with home replenishment. | Institutional ordering can support product access before home replenishment. |
| In January 2026, rehabilitation nutrition specialists highlighted updated sarcopenia nutrition guidance [16]. | Hospitals require structured muscle assessment and nutrition intervention. | Muscle-health criteria are becoming more structured. | Guideline-based products can support earlier nutrition planning. |
Source: Future Market Insights, Hepatic Sarcopenia Nutrition Market Report, 2026-2036.
Otsuka Pharmaceutical and Ajinomoto are used where liver-specific amino-acid nutrition is required. Abbott, Nestle Health Science and Danone Nutricia provide wider clinical nutrition ranges through established medical nutrition channels.
Meiji Holdings, Fresenius Kabi and Medtrition provide concentrated or modular nutrition formats. These products are useful where early satiety, bedtime intake or transition care makes a standard serving difficult to finish.
Who leads the hepatic sarcopenia nutrition market?
Public evidence does not establish one verified global market-share leader within the defined market.
Which companies have liver-specific amino-acid capability?
Otsuka Pharmaceutical and Ajinomoto have documented liver or amino-acid positions relevant to the category.
Which companies connect nutrition with broad clinical channels?
Abbott, Nestle Health Science, and Danone Nutricia operate broad medical nutrition platforms.
What should buyers evaluate before product adoption?
Buyers should check protein density, BCAA or leucine content, serving volume, taste, osmolality, allergen information and medical-food documentation. Product supply, dietitian materials, caregiver instructions and repeated home-use suitability should also be evaluated before approval.
How may competition change through 2036?
Competition through 2036 is expected to move towards products that are easier to consume repeatedly and remain available after discharge. Smaller servings, liver-relevant evidence and clear home-use support are anticipated to create higher preference across specialist pathways.
Representative Company Overview
| Company | Positioning | Verified market-relevant capability |
|---|---|---|
| Otsuka Pharmaceutical | Liver-specific nutrition supplier | Aminoleban provides a long-standing liver-oriented oral nutrition position. |
| Abbott | Broad medical nutrition supplier | Ensure Plus High Protein supports institutional and home oral nutrition. |
| Nestle Health Science | Broad medical nutrition supplier | Resource and related ranges provide high-protein clinical nutrition formats. |
| Danone Nutricia | Broad medical nutrition supplier | Fortimel PlantBased Protein added savory options in October 2025 [17]. |
| Ajinomoto | Amino-acid specialist | The company has documented BCAA research and liver-cirrhosis applications. |
| Meiji Holdings | Clinical nutrition supplier | MeiBalance products include concentrated liquid clinical nutrition formats. |
| Fresenius Kabi | Clinical nutrition supplier | Fresubin PRO COMPACT Drink provides 18 g protein in 125 ml [4]. |
| Medtrition | Modular nutrition specialist | ProSource Cup provides 20 g protein in a low-volume cup [9]. |
Research Methodology
The companies included in this section represent the structure of hepatic sarcopenia nutrition market and do not indicate a market ranking. Inclusion requires current evidence of oral or enteral nutrition used in liver-disease-associated sarcopenia or related high-protein clinical nutrition. Company websites, product documents, clinical guidance, official announcements and association sources are used for the assessment. Product relevance, source date and direct connection with the market boundary are considered during company selection. General wellness supplements and products without a defined clinical nutrition role are excluded. Segment shares and forecasts apply to the period from 2026 to 2036.
